SCRIBE BIOSCIENCES, INC.
Microenvironment on Demand (MOD), a droplet microfluidics platform for high-throughput single-cell combinatorial assays
- Sector
- Biotech
- Headquarters
- San Francisco, CA
- Total capital
- $4M
- Federal grants
- $2.3M
- 8 awards · 2018–2023
- Rank in peer group#35 of 36
- Private capital raised
- None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
- Federal contracts
- $1.7M
- 2 awards · Interior
- Rank in Biotech#149 of 4373
- Granted patents
- 1
- 7 pending · first 2025
- Rank in peer group#10 of 36
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase I · High throughput antibody discovery against cell membrane bound target proteins using innovative MOD technology for direct screening in single-cell assays$300K
- Federal grantHealth and Human S · Phase I · Microenvironment on Demand (MOD): A platform for single-cell cytotoxicity assays$350K
- Federal grantHealth and Human S · Phase I · A platform for engineering peptide ligase for building next generation peptide therapeutics.$225K
- Federal grantHealth and Human S · Phase I · A platform for integratingcell signaling and single cell transcriptomics.$350K
- Federal grantHealth and Human S · Phase I · A platform for integrating cell signaling and single cell transcriptomics.$350K
- Federal grantNSF · Phase I · SBIR Phase I: Controlled Organoid Synthesis with Fluorescence-Activated Cell Printing$225K
- Federal grantHealth and Human S · Phase I · A platform for coupling chromatin profiling with single cell transcriptomics$280K
Show 3 earlier federal awards
- Federal grantDefense · Phase I · Development of Gene-Encoded Monoclonal Antibody Potency Assay$221K
- Federal contractInterior · Development Of Gene-encoded Monoclonal Antibody Potency Assay$172K
- Federal contractInterior · Igf::ot::igf New Platform Technologies For Viral And Therapeutic Evolution Assays$1.5M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 36 peers
Line = medianBiotech · Platform
- Federal grantsBelow median
- Granted patents#10 · top 28%
- Linked publications#3 · top 8%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
No founders are linked to this company yet.
Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.
Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026
Claim this profile to add your teamWhat it has protected
USPTO · 1 granted of 8- GrantedPlatform for The Deterministic Assembly of Microfluidic DropletsUSPTOUS 12,383,900
- PendingHomogenous Assays In MicrodropletsUSPTOApplication 18156032
- PendingDeterministic Hybridoma Generation Via MicrofluidicsUSPTOApplication 17690427
Show all 8 patent records
- Platform for The Deterministic Assembly of Microfluidic DropletsAug 12, 2025 · US 12,383,900Granted
- Homogenous Assays In MicrodropletsAug 10, 2023 · Application 18156032Pending
- Deterministic Hybridoma Generation Via MicrofluidicsJan 19, 2023 · Application 17690427Pending
- Deterministic Hybridoma Generation Via MicrofluidicsApplication 63159181Pending
- Microfluidic CartridgesApplication PCTUS2023016024Pending
- Platform For The Deterministic Assembly Of Microfluidic DropletsApplication PCTUS2020032599Pending
- Microfluidic CartridgesApplication 63323374Pending
- Oligo-antibody Homogenous Assays In MicrodropletsApplication 63300459Pending
Recent research by its founders
- Impact of fed-batch process intensification on the productivity and product quality of two CHO cell lines expressing unique novel molecular format proteins20247 cites
- Characterizing cell interactions at scale with made-to-order droplet ensembles (MODEs)202257 cites
- Simple, Affordable, and Modular Patterning of Cells using DNA202112 cites
Related companies, and why
- Blaze Bioscience, Inc.Similar federal contract value in Biotech · $1.7M in contracts
- ADJUVANCE TECHNOLOGIES INC.Similar federal contract value in Biotech · $1.7M in contracts
- INGENIOUS TARGETING LABORATORY INC.Similar federal contract value in Biotech · $1.7M in contracts
- Strand Therapeutics Inc.Similar federal contract value in Biotech · $1.6M in contracts
- MAKSCIENTIFICSimilar federal contract value in Biotech · $1.6M in contracts
- INAEDIS, INCSimilar federal contract value in Biotech · $1.6M in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .